Dr. Xiangjiao Meng 孟祥姣
Chief Physician
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for lung cancer, esophageal cancer, and breast cancer. Integrates chemotherapy, immunotherapy, and targeted therapy into individualized treatment plans.
Dr. Meng is a Chief Physician and doctoral supervisor at Shandong Cancer Hospital. Trained under Academician Yu Jinming and as a visiting scholar at the University of Chicago under Professor Weichselbaum. Recipient of the China Young Cancer Scientist Award and 2023 Shandong Science and Technology Youth Award. Leads research on nine projects, including National Natural Science Foundation grants, and has published over 40 SCI papers.
Professional roles
- Designate Chair, Translational Medicine Expert Committee, Shandong Clinical Oncology Society
Name order: in Chinese the family name comes first (Meng Xiangjiao). Papers usually list the name as Xiangjiao Meng or Meng X.
Selected publications
143 papers on PubMed matched by name and affiliation; 58 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study. PubMed 42763051
- Cancer Lett, 2026 (senior author): Arginine methyltransferase PRMT3 suppresses tumor-intrinsic immunity via promoting cGAS methylation. PubMed 42641868
- Signal Transduct Target Ther, 2026 (senior author): Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice. PubMed 42894004
- Respir Res, 2026 (senior author): Prophylactic cranial irradiation versus active MRI surveillance for limited-stage small-cell lung cancer achieving response after chemoradiotherapy: a protocol for a randomized, controlled, multicenter, phase III trial. PubMed 42763407
- Ther Adv Med Oncol, 2026 (senior author): Efficacy and safety of different treatment regimens in patients with small cell lung cancer progressing from limited-stage to extensive-stage disease. PubMed 42621307
- Ther Adv Med Oncol, 2026 (senior author): Impact of hepatic radiotherapy on survival and safety outcomes in small cell lung cancer patients with liver metastases: a retrospective study. PubMed 42523939
- Ther Adv Med Oncol, 2026 (senior author): Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients. PubMed 42317257
- Transl Lung Cancer Res, 2026 (senior author): Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study. PubMed 42291371
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion